Technical Analysis for CSL - CSL Limited  

Grade Last Price % Change Price Change
D 273.720 -0.21% -0.580
CSL closed down 0.21 percent on Thursday, November 21, 2024, on 1.73 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -0.21%
Lower Bollinger Band Touch Weakness -0.21%
Oversold Stochastic Weakness -0.21%
Slingshot Bearish Bearish Swing Setup 0.87%
Lower Bollinger Band Walk Weakness 0.87%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 12 hours ago
3x Volume Pace about 12 hours ago
2x Volume Pace about 12 hours ago
1.5x Volume Pace about 12 hours ago
Up 1% 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CSL Limited   Description

CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Marketing Pharmaceutical Biotechnology Intellectual Property Biopharmaceutical Therapeutic Product Therapeutic Products In Vitro Pharmaceutical Products Pharmacology Diagnostic Products

Is CSL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 311.2911
52 Week Low 253.0309
Average Volume 575,141
200-Day Moving Average 288.568
50-Day Moving Average 289.610
20-Day Moving Average 283.577
10-Day Moving Average 279.770
Average True Range 4.514
RSI (14) 32.89
ADX 27.59
+DI 17.834
-DI 34.061
Chandelier Exit (Long, 3 ATRs) 282.487
Chandelier Exit (Short, 3 ATRs) 283.563
Upper Bollinger Bands 296.450
Lower Bollinger Band 270.704
Percent B (%b) 0.12
BandWidth 9.079
MACD Line -4.998
MACD Signal Line -3.831
MACD Histogram -1.1669
Fundamentals Value
Market Cap 124.54 Billion
Num Shares 455 Million
EPS 4.62
Price-to-Earnings (P/E) Ratio 59.31
Price-to-Sales 10.41
Price-to-Book 14.49
PEG Ratio 0.00
Dividend 2.94
Dividend Yield 1.07%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 279.390
Resistance 3 (R3) 279.803 278.327 278.445
Resistance 2 (R2) 278.327 276.883 278.120 278.130
Resistance 1 (R1) 276.023 275.991 275.285 275.610 277.815
Pivot Point 274.547 274.547 274.178 274.340 274.547
Support 1 (S1) 272.243 273.103 271.505 271.830 269.625
Support 2 (S2) 270.767 272.211 270.560 269.310
Support 3 (S3) 268.463 270.767 268.995
Support 4 (S4) 268.050